The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by NRF2 silencing

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Choi, Bo Hyun ^a   Ryoo, In Geun ^a   Kang, Han Chang ^a   Kwak, Mi Kyoung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MESSENGER RNA; PEROXIREDOXIN 3; PHEOPHORBIDE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CHLOROPHYLL; PHEOPHORBIDE A; RADIOSENSITIZING AGENT; SMALL INTERFERING RNA; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; COLON CARCINOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; GENE SILENCING; GLIOBLASTOMA; HT 29 CELL LINE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MULTIPLE CANCER; NRF2 GENE; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; REGULATOR GENE; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; COLON TUMOR; FEMALE; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LASER; LENTIVIRINAE; LOW LEVEL LASER THERAPY; METABOLISM; NEOPLASMS; PHOTOCHEMOTHERAPY; TUMOR CELL LINE;

ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHLOROPHYLL; COLONIC NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENETIC VECTORS; HUMANS; LASER THERAPY; LASERS; LENTIVIRUS; NEOPLASM PROTEINS; NEOPLASMS; NF-E2-RELATED FACTOR 2; PEROXIREDOXIN III; PHOTOCHEMOTHERAPY; RADIATION-SENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC;

EID: 84907187838     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107158     Document Type: Article

References (60)

1. Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3: 380-387.
2. Hopper C (2000) Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol 1: 212-219.
3. McBride G (2002) Studies expand potential uses of photodynamic therapy. J Natl Cancer Inst 94: 1740-1742.
4. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, et al. (1998) Photodynamic therapy. J Natl Cancer Inst 90: 889-905.
5. Sharman WM, Allen CM, van Lier JE (2000) Role of activated oxygen species in photodynamic therapy. Methods Enzymol 319: 376-400.
6. Buytaert E, Dewaele M, Agostinis P (2007) Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta 1776: 86-107.
7. Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and antitumour immunity. Nat Rev Cancer 6: 535-545.
8. Nowis D, Makowski M, Stoklosa T, Legat M, Issat T, et al. (2005) Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol 52: 339-352.
9. Park YJ, Lee WY, Hahn BS, Han MJ, Yang WI, et al. (1989) Chlorophyll derivatives - a new photosensitizer for photodynamic therapy of cancer in mice. Yonsei Med J 30: 212-218.
10. Chan JY, Tang PM, Hon PM, Au SW, Tsui SK, et al. (2006) Pheophorbide a, a major antitumor component purified from Scutellaria barbata, induces apoptosis in human hepatocellular carcinoma cells. Planta Med 72: 28-33.
11. Li WT, Tsao HW, Chen YY, Cheng SW, Hsu YC (2007) A study on the photodynamic properties of chlorophyll derivatives using human hepatocellular carcinoma cells. Photochem Photobiol Sci 6: 1341-1348.
12. Xodo LE, Rapozzi V, Zacchigna M, Drioli S, Zorzet S (2012) The chlorophyll catabolite pheophorbide a as a photosensitizer for the photodynamic therapy. Curr Med Chem 19: 799-807.
13. Hajri A, Coffy S, Vallat F, Evrard S, Marescaux J, et al. (1999) Human pancreatic carcinoma cells are sensitive to photodynamic therapy in vitro and in vivo. Br J Surg 86: 899-906.
14. Hibasami H, Kyohkon M, Ohwaki S, Katsuzaki H, Imai K, et al. (2000) Pheophorbide a, a moiety of chlorophyll a, induces apoptosis in human lymphoid leukemia molt 4B cells. Int J Mol Med 6: 277-279.
15. Tang PM, Chan JY, Au SW, Kong SK, Tsui SK, et al. (2006) Pheophorbide a, an active compound isolated from Scutellaria barbata, possesses photodynamic activities by inducing apoptosis in human hepatocellular carcinoma. Cancer Biol Ther 5: 1111-1116.
16. Lee WY, Lim DS, Ko SH, Park YJ, Ryu KS, et al. (2004) Photoactivation of pheophorbide a induces a mitochondrial-mediated apoptosis in Jurkat leukaemia cells. J Photochem Photobiol B 75: 119-126.
17. Tang PM, Liu XZ, Zhang DM, Fong WP, Fung KP (2009) Pheophorbide a based photodynamic therapy induces apoptosis via mitochondrial-mediated pathway in human uterine carcinosarcoma. Cancer Biol Ther 8: 533-539.
18. Hoi SW, Wong HM, Chan JY, Yue GG, Tse GM, et al. (2012) Photodynamic therapy of Pheophorbide a inhibits the proliferation of human breast tumour via both caspase-dependent and -independent apoptotic pathways in in vitro and in vivo models. Phytother Res 26: 734-742.
19. Hajri A, Wack S, Meyer C, Smith MK, Leberquier C, et al. (2002) In vitro and in vivo efficacy of photofrin and pheophorbide a, a bacteriochlorin, in photodynamic therapy of colonic cancer cells. Photochem Photobiol 75: 140-148.
20. Wlcek K, Stieger B (2013) ATP-binding cassette transporters in liver. Biofactors.
21. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95: 15665-15670.
22. Natarajan K, Xie Y, Baer MR, Ross DD (2012) Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 83: 1084-1103.
23. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, et al. (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64: 1242-1246.
24. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 99: 15649-15654.
25. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 236: 313-322.
26. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, et al. (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86.
27. Kobayashi M, Yamamoto M (2005) Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid Redox Signal 7: 385-394.
28. Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT (2010) Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal 13: 1713-1748.
29. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, et al. (2003) Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 278: 8135-8145.
30. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, et al. (2002) Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196-5203.
31. Kensler TW, Wakabayashi N, Biswal S (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116.
32. Cho HY, Kleeberger SR (2010) Nrf2 protects against airway disorders. Toxicol Appl Pharmacol 244: 43-56.
33. Jaramillo MC, Zhang DD (2013) The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27: 2179-2191.
34. Chen CC, Chu CB, Liu KJ, Huang CY, Chang JY, et al. (2013) Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochem Pharmacol 86: 872-887.
35. Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, et al. (2008) Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 45: 537-546.
36. Shim GS, Manandhar S, Shin DH, Kim TH, Kwak MK (2009) Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med 47: 1619-1631.
37. Kocanova S, Buytaert E, Matroule JY, Piette J, Golab J, et al. (2007) Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. Apoptosis 12: 731-741.
38. Hagiya Y, Adachi T, Ogura S, An R, Tamura A, et al. (2008) Nrf2-dependent induction of human ABC transporter ABCG2 and heme oxygenase-1 in HepG2 cells by photoactivation of porphyrins: biochemical implications for cancer cell response to photodynamic therapy. J Exp Ther Oncol 7: 153-167.
39. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, et al. (2011) NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res 71: 2260-2275.
40. Moor AC (2000) Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B 57: 1-13.
41. Hayes JD, McMahon M (2009) NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188.
42. Mitsuishi Y, Motohashi H, Yamamoto M (2012) The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2: 200.
43. Lage H, Dietel M (2000) Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol 1: 169-175.
44. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59: 4237-4241.
45. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, et al. (2000) Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 60: 3514-3521.
46. Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, et al. (2007) The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 13: 2463-2470.
47. Usuda J, Tsunoda Y, Ichinose S, Ishizumi T, Ohtani K, et al. (2010) Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. Lung Cancer 67: 198-204.
48. Klaassen CD, Slitt AL (2005) Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab 6: 309-328.
49. Urquhart BL, Tirona RG, Kim RB (2007) Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47: 566-578.
50. Hayashi A, Suzuki H, Itoh K, Yamamoto M, Sugiyama Y (2003) Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun 310: 824-829.
51. Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD (2005) Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab Dispos 33: 956-962.
52. Adachi T, Nakagawa H, Chung I, Hagiya Y, Hoshijima K, et al. (2007) Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol 6: 335-348.
53. Oleinick NL, Morris RL, Belichenko I (2002) The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 1: 1-21.
54. Galluzzi L. , Kepp O., Krautwald S., Kroemer G., Linkermann A. (2014) Molecular mechanisms of regulated necrosis. Semin Cell Dev Biol
55. Kaczmarek A, Vandenabeele P, Krysko DV (2013) Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity 38: 209-223.
56. Vanlangenakker N, Vanden Berghe T, Vandenabeele P (2012) Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 19: 75-86.
57. Shen HM, Lin Y, Choksi S, Tran J, Jin T, et al. (2004) Essential roles of receptor-interacting protein and TRAF2 in oxidative stress-induced cell death. Mol Cell Biol 24: 5914-5922.
58. Xu X, Chua CC, Kong J, Kostrzewa RM, Kumaraguru U, et al. (2007) Necrostatin-1 protects against glutamate-induced glutathione depletion and caspase-independent cell death in HT-22 cells. J Neurochem 103: 2004-2014.
59. Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK (2008) Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett 260: 96-108.
60. Manandhar S, Choi BH, Jung KA, Ryoo IG, Song M, et al. (2012) NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity. Free Radic Biol Med 52: 1773-1785.